Increasing dietary nitrate has no effect on cancellous bone loss or fecal microbiome in ovariectomized rats

Melissa N. Conley1,2, Cooper Roberts1, Thomas J. Sharpton2,3, Urszula T. Iwaniec2,4 and Norman G. Hord1,2

1 School of Biological and Population Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA
2 Center for Healthy Aging Research, Oregon State University, Corvallis, OR, USA
3 Departments of Microbiology and Statistics, College of Science, Oregon State University, Corvallis, OR, USA
4 Skeletal Biology Laboratory, School of Biological and Population Health Sciences, Oregon State University, Corvallis, OR, USA

Scope: Studies suggest diets rich in fruit and vegetables reduce bone loss, although the specific compounds responsible are unknown. Substrates for endogenous nitric oxide (NO) production, including organic nitrates and dietary nitrate, may support NO production in age-related conditions, including osteoporosis. We investigated the capability of dietary nitrate to improve NO bioavailability, reduce bone turnover and loss.

Methods and results: Six-month-old Sprague Dawley rats [30 ovariectomized (OVX) and 10 sham-operated (sham)] were randomized into three groups: (i) vehicle (water) control, (ii) low-dose nitrate (LDN, 0.1 mmol nitrate/kg bw/day), or (iii) high-dose nitrate (HDN, 1.0 mmol nitrate/kg bw/day) for three weeks. The sham received vehicle. Serum bone turnover markers; bone mass, mineral density, and quality; histomorphometric parameters; and fecal microbiome were examined. Three weeks of LDN or HDN improved NO bioavailability in a dose-dependent manner. OVX resulted in cancellous bone loss, increased bone turnover, and fecal microbiome changes. OVX increased relative abundances of Firmicutes and decreased Bacteroidaceae and Alcaligenaceae. Nitrate did not affect the skeleton or fecal microbiome.

Conclusion: These data indicate that OVX affects the fecal microbiome and that the gut microbiome is associated with bone mass. Three weeks of nitrate supplementation does not slow bone loss or alter the fecal microbiome in OVX.

Keywords: Dietary nitrate / Nitric oxide / Osteoporosis / Postmenopause / Vegetables

Additional supporting information may be found in the online version of this article at the publisher’s web-site

1 Introduction

Osteoporosis is a common metabolic bone disease, affecting a third of women and a fifth of men over the age of 65 years [1]. In the United States, associated annual health care costs are estimated to be over $20 billion. Menopause-induced estrogen deficiency causes an increase in bone turnover [2]. Increased bone resorption relative to bone formation contributes to reduced bone quality and bone mineral density (BMD), and low BMD is associated with increased fracture risk in postmenopausal women [2, 3].

Some observational studies report that fruit and vegetable consumption is associated with increased bone mineral
content (BMC) and BMD [4–8]. Nitrates, present in high concentrations in leafy green and root vegetables, may serve as a dietary component that supports bone health. Since dietary nitrate enhances NO bioavailability in a dose-dependent fashion [9], this dietary compound may be a viable option for reducing bone loss. Vegetable intake accounts for ~80% of dietary nitrate consumption in human diets [10]; dietary nitrates can be reduced to nitric oxide (NO) via non-enzymatic reduction by lingual bacteria and a variety of mammalian reductases and increase NO bioavailability through the nitrate-nitrite-NO pathway [11, 12]. Gastric metabolism of nitrate and nitrite is associated with both health benefits and risks [13], including the formation of potentially carcinogenic nitrosamines promoted by nitrites in processed meats which can be inhibited by flavonoids and other compounds in vegetables [14]. Importantly, both the European Food Standards Agency (EFSA) and a recent NHLBI panel concluded that current research does not support a role for nitrate consumed as vegetables as a carcinogen [10].

NO plays extensive roles in physiological processes, ranging from vascular homeostasis to host defense, cellular energetics, and nerve transmission [15]. There are two major sources of endogenous NO in the body: the nitric oxide synthase (NOS) system that uses L-arginine as a substrate and the mammalian nitrate-nitrite-NO pathway that uses dietary nitrate and nitrate derived from oxidation of NOS-derived NO. Under normal conditions, these contribute about equally to NO homeostasis [16]. The mammalian nitrate-nitrite-NO pathway is involved in the regulation of blood flow and blood pressure, cell signaling, and tissue responses to hypoxia [17]. During aging and hypoxia/ischemia, the highly oxygen-dependent NOSs become less effective in generating NO, in contrast to the nitrate-nitrite-NO pathway, in which NO formation from nitrite reduction in tissues is enhanced during hypoxia and low pH [18]. Aging is associated with decreased endothelial NOS-dependent NO synthesis and endothelium-dependent vasodilation, suggesting a possible role for dietary nitrates to support NO production in age-related conditions like osteoporosis. [19, 20].

Organic nitrates (e.g., nitroglycerin [NTG]) have been used to treat cardiovascular disorders for over 100 years [21]. Postmenopausal women using organic nitrates had improved BMD compared to non-nitrate users [20]. Studies in an ovariectomized (OVX) animal model of bone loss demonstrated increased NO bioavailability using NTG as an NO donor and improved BMD and decreased bone turnover [22–24]. While pilot studies in humans suggested a beneficial effect, the Phase III NOVEL trial found no significant effect of NTG on lumbar spine BMD after two years of intervention [25–27].

The gut microbiome may also affect bone mass [28] through the production of NO in the gut [29]. Several investigations have shown the gut microbiome plays a role in regulating bone mass suggesting interactions between diet and the gut microbiome could have important consequences for bone loss [28, 30, 31]. Since we hypothesized that fecal microbiome composition is associated with dietary nitrate status and bone loss, we interrogated the dietary nitrate-dependent changes in the fecal microbiome. The objectives of this study were to quantify the ability of dietary nitrate to improve NO bioavailability, reduce bone turnover and loss, as well as alter the fecal microbiome composition using an OVX rat model.

2 Materials and methods

2.1 Experimental design

A total of 40 six-month-old female Sprague Dawley rats [30] ovariectomized (OVX) and 10 sham-operated (sham) at 5.5 month of age] were purchased from Charles River Laboratory (Hollister, California). Three days after arrival at Oregon State University OVX rats were randomized by weight into 1 of 3 treatment groups (n = 10 per group): (i) vehicle (water) control, (ii) low-dose nitrate (LDN, 0.1 mmol nitrate/kg bw/day), or (iii) high-dose nitrate (HDN, 1.0 mmol nitrate/kg bw/day). The sham controls received vehicle. At study initiation, sodium nitrate was added to water at 0.14 or 1.4 g/L to achieve 0.1 or 1.0 mmol nitrate intake per kilogram body weight per day; the concentration of nitrate was adjusted during body weight gain to assure consistent dietary nitrate concentration throughout the study. Food (TD.2018 chow, Teklad Lab Animal Diets, 118/5.4 nmol of nitrate/nitrite per g) was provided ad libitum to all animals. The rats were single-housed and maintained on a 12-hour light:12-hour dark cycle for the three-week duration of study. The Institutional Animal Care and Use Committee at Oregon State University approved the experimental protocol under ACUP 4532. Animals were maintained in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

Food and water consumption and body weight were measured twice a week. These data were used for adjusting nitrate levels in the water to maintain appropriate nitrate concentrations throughout the study. Water was replaced every other day for the duration of experiment. The fluorochrome calcein (20mg/kg, Sigma-Aldrich, St. Louis, MO), was injected subcutaneously 9 and 2 days before sacrifice to label mineralizing bone. Fecal samples were collected at the end of the three-week study and stored at –80°C. For tissue collection all rats were fasted overnight, then anesthetized with 2–3% isoflurane delivered in oxygen, and death was induced by exsanguination from the heart. Serum and blood were collected and stored at –80°C for measurement of serum global markers of bone turnover and blood nitrate and nitrite levels. Uteri and abdominal white adipose tissue (WAT) were excised and weighed. Tibiae were removed and stored in 70% ethanol for analysis using dual-energy X-ray absorptiometry (DXA), microcomputed tomography (μCT), and histomorphometry.
2.2 Quantification of blood nitrate and nitrite levels

2.2.1 Blood collection and pretreatment

Whole blood was obtained by cardiac puncture and pre-treated for nitrate and nitrite analysis, as described previously [32]. Briefly, heparinized whole blood was mixed with nitrite-preserving solution \([\text{K}_3\text{Fe(CN)}_6, \text{N-ethylmaleimide, water, Nonidet P-40}]\) and kept frozen at \(-20^\circ\)C until analysis. For nitrate analysis, heparinized whole blood was mixed with deionized water at a 1:9 ratio between the blood and water and kept frozen at \(-80^\circ\)C until analysis.

2.2.2 Nitrate and nitrite analysis

Nitrate and nitrite content was analyzed using a standard gas phase chemiluminescence method (NO Analyzer (NOA), model 280i, GE Analytical Instruments, Boulder, CO) with helium as carrier gas, as described elsewhere [32]. Briefly, for nitrate analysis, samples were injected into purge vessel of the NO analyzer containing 7 mL of heated (95°C) vanadium chloride (0.8 g of vanadium chloride dissolved in 100 mL of 1M hydrochloric acid) solution. For nitrite analysis, samples were deproteinized with methanol, centrifuged for 3 min at 15 000 rpm, and then supernatants were injected into the purge vessel of the NOA containing 7 mL of tri-iodide (1 g potassium iodide, 0.65 g iodine, 20 mL water and 70 mL glacial acetic acid) solution. The concentration of nitrate and nitrite in analyzed samples was deduced from standard concentration vs. peak area curves constructed with sodium nitrate (10 \(\mu\)M) and sodium nitrite (1 \(\mu\)M), respectively. A correction for the nitrite concentration in nitrite-preserving solution and methanol, nitrate concentration in deionized water, and molar mass of sodium was made when calculating levels of nitrate and nitrite ions in the samples analyzed.

Average daily nitrate intake from food was derived from average daily food intake and quantification of dietary nitrate present in TD.2018 diet, as described in the methods section. Average daily nitrate intake from water was derived from average daily water intake and sodium nitrate concentrations in water provided. Total average daily nitrate intake was determined by totaling average daily nitrate intake from food and water.

2.3 Serum markers of bone turnover

Serum osteocalcin was measured using a rat Gla-osteocalcin High Sensitive EIA kit obtained from Clontech Takara. Serum C-terminal telopeptide (CTx) was measured using a rat CTx ELISA kit from Life Sciences Advanced Technologies (St. Petersburg, FL).

2.2 Quantification of blood nitrate and nitrite levels

2.2.2 Nitrate and nitrite analysis

Nitrate and nitrite content was analyzed using a standard gas phase chemiluminescence method (NO Analyzer (NOA), model 280i, GE Analytical Instruments, Boulder, CO) with helium as carrier gas, as described elsewhere [32]. Briefly, for nitrate analysis, samples were injected into purge vessel of the NO analyzer containing 7 mL of heated (95°C) vanadium chloride (0.8 g of vanadium chloride dissolved in 100 mL of 1M hydrochloric acid) solution. For nitrite analysis, samples were deproteinized with methanol, centrifuged for 3 min at 15 000 rpm, and then supernatants were injected into the purge vessel of the NOA containing 7 mL of tri-iodide (1 g potassium iodide, 0.65 g iodine, 20 mL water and 70 mL glacial acetic acid) solution. The concentration of nitrate and nitrite in analyzed samples was deduced from standard concentration vs. peak area curves constructed with sodium nitrate (10 \(\mu\)M) and sodium nitrite (1 \(\mu\)M), respectively. A correction for the nitrite concentration in nitrite-preserving solution and methanol, nitrate concentration in deionized water, and molar mass of sodium was made when calculating levels of nitrate and nitrite ions in the samples analyzed.

Average daily nitrate intake from food was derived from average daily food intake and quantification of dietary nitrate present in TD.2018 diet, as described in the methods section. Average daily nitrate intake from water was derived from average daily water intake and sodium nitrate concentrations in water provided. Total average daily nitrate intake was determined by totaling average daily nitrate intake from food and water.

2.4 Dual-energy X-ray absorptiometry

Tibial bone mineral content (BMC; mg) and area (cm^2) were measured ex vivo using dual-energy x-ray absorptiometry (DXA; Piximus; Lunar Corp., Madison, WI). Bone mineral density (BMD) was calculated as BMC per area (mg/cm^2).

2.5 Microcomputed tomography

Nondestructive three-dimensional evaluation of bone microarchitecture was completed using \(\mu\)CT. Tibiae were scanned at a voxel size of 16\(\times\)16\(\times\)16 \(\mu\)m (55 kVp x-ray voltage, 145 \(\mu\)A intensity, and 200 ms integration time) using a Scanco \(\mu\)CT40 scanner (Scanco Medical AG, Basserdorf, Switzerland). Filtering parameters sigma and support were set to 0.8 and 1, respectively. Threshold for analysis was determined empirically and set at 245 (range, 0–1000) for both cancellous bone and cortical bone. Cancellous bone was assessed in 94 slices (1504 \(\mu\)m) (1504 \(\mu\)m distal to the growth plate) and 33 \(\pm\) 1 slices (528 \(\pm\) 16\(\mu\)m) in the proximal tibia metaphysis and proximal tibia epiphysis, respectively (Supporting Information Fig. 1: VOIs). Cortical bone was assessed at 62 slices (992 \(\mu\)m) distal to the midshaft. Midshaft was defined as midpoint between the top and bottom of each tibia. Direct cancellous bone measurements included cancellous bone volume fraction (bone volume/tissue volume, BV/TV; volume of tissue occupied by cancellous bone, %), trabecular number (number of trabecular intercepts, mm\(^{-1}\)), trabecular thickness (mean thickness of individual trabeculae, \(\mu\)m), and trabecular separation (mean distance between trabeculae, \(\mu\)m). Direct cortical measurements included cross-sectional volume (volume of cortical bone and bone marrow, mm\(^3\)), cortical volume (mm\(^3\)), marrow volume (mm\(^3\)), and cortical thickness (\(\mu\)m).

2.6 Histomorphometry

Histological methods applied here have been previously described [33] and are summarized in Supporting Information File 1. Histomorphometric data were collected using the OsteoMeasure System (OsteoMetrics, Inc., Atlanta, GA, USA) and are reported using standard two-dimensional nomenclature (Dempster, 2012).

2.7 Fecal DNA isolation and 16S amplicon sequencing

Samples were processed as previously described [34]. Fecal DNA was isolated using QIAamp DNA stool mini-kits (Qiagen, Valencia, CA) per manufacturer’s instructions. 16S rRNA PCR amplification was conducted according to established methods [35]. Briefly, each sample’s extracted DNA was subjected to PCR reactions to amplify the V4 region
Table 1. Average body weight, food and water intake, daily nitrate intake, uterine weights, and abdominal WAT across each group

| Endpoint                        | Sham-Operated | Ovariectomized | FDR-adjusted p-value comparing the four groups |
|---------------------------------|---------------|----------------|-----------------------------------------------|
|                                 | Control (n = 10) | Low NO3 (n = 10) | High NO3 (n = 10) |
| Body weight (g)                 | 314.3 ± 5.9 | 370.1 ± 10.38<sup>a</sup> | 368.6 ± 9.94<sup>a</sup> | 365.8 ± 9.97<sup>a</sup> | 0.004 |
| Average daily food intake (g/d) | 16.24 ± 0.43 | 18.97 ± 0.71 | 18.77 ± 0.65 | 17.91 ± 0.45 | 0.110 |
| Average daily water intake (mL/g)| 22.48 ± 1.77 | 17.16 ± 0.95 | 18.73 ± 1.36 | 21.29 ± 1.15 | 0.398 |
| Average daily nitrate from food (μM/d)| 2.35 ± 0.06 | 2.75 ± 0.1 | 2.72 ± 0.09 | 2.5 ± 0.06 | 0.110 |
| Average daily nitrate from water (μM/d)| – – | – – | 30.85 ± 2.24 | 350.67 ± 18.91<sup>c</sup> | N/A |
| Average total daily nitrate intake (μM/d)| 2.35 ± 0.06 | 2.75 ± 0.1 | 33.57 ± 2.29<sup>b</sup> | 353.27 ± 18.91<sup>b,c</sup> | 0.003 |
| Uterine weight (g)              | 0.728 ± 0.060 | 0.157 ± 0.01<sup>a</sup> | 0.155 ± 0.01<sup>a</sup> | 0.1612 ± 0.01<sup>a</sup> | 0.003 |
| Abdominal white adipose tissue weight (g)| 9.37 ± 0.54 | 13.22 ± 1.06 | 14.15 ± 1.44 | 13.39 ± 0.51 | 0.096 |

Data are mean ± SE
a) Different than sham, p < 0.05.
b) Different than OVX control, p < 0.05.
c) Different than low NO3, p < 0.05.
*The Benjamini–Hochberg method for maintaining the family-wise error rate at 5% was used to adjust for multiple comparisons.
Food intake, water intake, and body weights were collected twice per week for duration of the study.

3 Results

3.1 Dietary nitrate intakes

Average daily nitrate intakes for each group are shown in Table 1. There were no differences in average daily nitrate intake from food between sham, OVX vehicle, LDN, or HDN groups. Total daily nitrate intakes were not significantly different between OVX and sham, while LDN and HDN groups had significantly higher total nitrate intake compared to OVX vehicle.
Figure 1. (a) OVX had no effect on blood nitrate levels and increasing dietary nitrate resulted in increased blood nitrate levels and (b) OVX had no effect on blood nitrite levels compared to sham, while significantly increased blood nitrite levels were observed in the OVX-HDN treatment group. OVX, ovariectomized; LDN, low-dose nitrate 0.1 mmol sodium nitrate kg/day; and HDN, high-dose nitrate 1 mmol sodium nitrate kg/day. Data represent means ±SE (n = 10 rats/group). *Differences were considered significant at Benjamini-Hochberg adjusted p < 0.05; Groups not sharing a superscript are significantly different.

3.2 Effects of dietary nitrate on blood nitrate and nitrite levels

The effects of OVX and dietary nitrate supplementation on blood nitrate and blood nitrite levels are summarized in Fig. 1. There were no significant differences in blood nitrate levels between OVX vehicle and sham controls (Fig. 1A). The LDN and HDN groups had significant increases in blood nitrate compared to OVX vehicle. There were also no significant differences in blood nitrite levels between OVX vehicle and shams (Fig. 1B). There were no significant differences in blood nitrite levels in LDN group compared to vehicle, while the HDN group had significantly higher blood nitrite levels compared to OVX vehicle and LDN groups.

3.3 Effects of dietary nitrate on food and water intake, body weight, uterine weight, and abdominal white adipose tissue weight

Average daily food and water intake, body weights, uterine weights, and abdominal white adipose tissue (WAT) weights for each group are shown in Table 1. All OVX groups had significantly increased body weight and decreased uterine weight compared to sham controls with no differences observed between OVX, LDN, and HDN groups. There were no significant differences in food intake between OVX and sham, or OVX vehicle, LDN, and HDN groups. There were no observed differences in WAT weights between groups.

3.4 Effects of ovariectomy on bone

The effects of OVX on bone mass and architecture are summarized in Table 2. Significant differences in tibial BMC, bone area, or BMD were not detected between OVX rats treated with vehicle, LDN, or HDN. Significant differences in cancellous bone (BV/TV, trabecular number, trabecular thickness, and trabecular separation) were not observed among treatment groups. Similarly, significant differences in cortical endpoints (cross-sectional area, cortical volume, marrow volume, or cortical thickness) were not detected among OVX rats treated with vehicle, LDN, or HDN. Histological analyses of proximal tibia metaphysis revealed there were no significant differences in mineral apposition rate, mineralizing perimeter, or bone formation rate between OVX vehicle, LDN, or HDN groups (Fig. 2A–D). Significant differences in cortical endpoints (cross-sectional area, cortical volume, marrow volume, or cortical thickness) were not detected between OVX vehicle and sham.

3.5 Effects of dietary nitrate supplementation on bone in ovariectomized rats

The effects of dietary nitrate supplementation on bone are summarized in Table 2. Significant differences in tibial BMC, bone area, or BMD were not detected between OVX rats treated with vehicle, LDN, or HDN. Significant differences in cancellous bone (BV/TV, trabecular number, trabecular thickness, and trabecular separation) were not observed among treatment groups. Similarly, significant differences in cortical endpoints (cross-sectional area, cortical volume, marrow volume, or cortical thickness) were not detected among OVX rats treated with vehicle, LDN, or HDN. Histological analyses of proximal tibia metaphysis revealed there were no significant differences in mineral apposition rate, mineralizing perimeter, or bone formation rate between OVX vehicle, LDN, or HDN groups (Fig. 2A–D). Significant differences in cortical endpoints (cross-sectional area,
Rats were ovariectomized at 6 months of age and treated with one of two doses of nitrate for three weeks. BMC, bone mineral content; BMD, bone mineral density.

*The Benjamini–Hochberg method for maintaining the family-wise error rate at 5% was used to adjust for multiple comparisons.

c) Different than low NO3, p < 0.05

Table 2. Dietary nitrate had no effects on BMC and BMD in total tibia, on cancellous bone in the proximal tibial metaphysis or proximal tibial epiphysis and on cortical bone in the tibial diaphysis in ovariectomized Sprague Dawley rats

| Endpoint | Sham-Operated | Ovariectomized |
|----------|---------------|----------------|
|          | Control (n = 10) | Control (n = 10) | Low NO3 (n = 10) | High NO3 (n = 10) | FDR-adjusted p-value comparing the four groups |
| Total Tibia | Bone Area (cm²) | 2.40 ± 0.05 | 2.62 ± 0.06 | 2.55 ± 0.03 | 2.56 ± 0.03 | 0.172 |
|          | BMC (g) | 0.364 ± 0.009 | 0.373 ± 0.015 | 0.361 ± 0.008 | 0.366 ± 0.010 | 1.000 |
|          | BMD (g/cm²) | 0.152 ± 0.005 | 0.142 ± 0.003 | 0.142 ± 0.002 | 0.143 ± 0.003 | 1.000 |
| microComputed Tomography | Proximal Tibia Epiphysis (cancellous bone) | Bone Volume/Tissue Volume (%) | 43.52 ± 1.47 | 37.14 ± 1.12 | 38.42 ± 1.12 | 37.50 ± 1.15 | 0.041 |
|          | Trabecular Number (1/mm) | 5.13 ± 0.19 | 4.54 ± 0.11 | 4.69 ± 0.12 | 4.69 ± 0.18 | 0.540 |
|          | Trabecular Thickness (μm) | 98 ± 3 | 95 ± 2 | 95 ± 2 | 94 ± 2 | 1.000 |
|          | Trabecular Spacing (μm) | 182 ± 6 | 212 ± 6 | 202 ± 5 | 208 ± 7 | 0.088 |
| Proximal Tibia Metaphysis (cancellous bone) | Bone Volume/Tissue Volume (%) | 28.95 ± 3.22 | 14.14 ± 1.09 | 14.77 ± 1.72 | 14.31 ± 1.24 | 0.003 |
|          | Trabecular Number (1/mm) | 5.44 ± 0.26 | 3.93 ± 0.22 | 3.97 ± 0.15 | 3.78 ± 0.20 | 0.003 |
|          | Trabecular Thickness (μm) | 71 ± 3 | 64 ± 2 | 63 ± 2 | 63 ± 1 | 0.446 |
|          | Trabecular Spacing (μm) | 168 ± 10 | 252 ± 16 | 244 ± 10 | 261 ± 15 | 0.003 |
| Midtibia Metaphysis (cortical bone) | Cross-Sectional Volume (mm³) | 5.96 ± 0.19 | 6.43 ± 0.26 | 6.05 ± 0.15 | 6.19 ± 0.14 | 1.000 |
|          | Cortical Volume (mm³) | 4.56 ± 0.14 | 4.93 ± 0.17 | 4.73 ± 0.12 | 4.78 ± 0.11 | 1.000 |
|          | Marrow Volume (mm³) | 1.40 ± 0.07 | 1.50 ± 0.10 | 1.32 ± 0.04 | 1.41 ± 0.06 | 1.000 |
|          | Cortical Thickness (μm) | 654 ± 13 | 676 ± 10 | 677 ± 14 | 673 ± 11 | 1.000 |
|          | *b* polar (mm²) | 5.96 ± 0.37 | 7.06 ± 0.55 | 6.20 ± 0.29 | 6.44 ± 0.29 | 1.000 |

Data are mean ± SE
a) Different than sham, p < 0.05
b) Different than OVX control, p < 0.05
c) Different than low NO3, p < 0.05

*The Benjamini–Hochberg method for maintaining the family-wise error rate at 5% was used to adjust for multiple comparisons.

BMC, bone mineral content; BMD, bone mineral density.

Rats were ovariectomized at 6 months of age and treated with one of two doses of nitrate for three weeks.

cortical area, marrow area, or cortical thickness) were not detected between OVX, LDN, and HDN groups.

3.6 Effects of dietary nitrate supplementation on serum biochemical markers of bone turnover

The effects of OVX and dietary nitrate supplementation on serum biochemical markers of bone resorption (CTx) and bone formation (osteocalcin) are show in Fig. 3E and F. There were no significant differences in osteocalcin or CTx levels between OVX vehicle group, LDN, or HDN.

3.7 Effects of ovariectomy and dietary nitrate supplementation on fecal microbiota composition

In order to identify possible gut microbiota signatures with OVX or dietary nitrate, we compared the fecal microbiota composition of sham rats to OVX rats treated with vehicle, LDN, or HDN. We first assessed the intersample diversity between the sham and OVX rats. We used UniFrac, which normalizes intersample taxonomic differences by the phylogenetic diversity of the microbial lineages observed in the samples (i.e., samples containing more phylogenetically similar taxa produce a relatively lower distance). A principal coordinates analysis (PCoA) of fecal samples based on their weighted UniFrac distances reveals that samples weakly but significantly cluster by OVX status, as supported by a permutational multivariate analysis of variance (R² = 0.17, p = 0.017) (Fig. 3B). This finding suggests the sham and OVX rats exhibit microbial communities with different evolutionary histories. These results are qualitatively consistent with those obtained using unweighted UniFrac and indicate that there are distinct phylogenetic differences in the gut microbiome between sham and OVX rats. We also observe significant differences between within-group and between group beta diversity between sham and OVX (Supporting Information Fig. 2). However, we did not observe any clustering between OVX vehicle, LDN, or HDN groups based on UniFrac distances (Fig. 3A), or significant differences between within-group and between-group beta-diversity variability across these groups (Supporting Information Fig. 2).
We then explored the structure of these communities at various taxonomic levels to understand potential taxonomic signatures that may stratify samples based on OVX status. Using 16S rRNA ribosomal genes as a marker, sequences were clustered into operational taxonomic units (OTUs) using a threshold of 97% sequence similarity from the GreenGenes database [39] using the QIIME open-reference OTU-picking protocol. OTUs were then taxonomically annotated using UCLUST. As expected, given prior characterizations of the rodent gut microbiome, all rats were dominated by the phyla Bacteroidetes and Firmicutes [40, 41]. We found a trend of increases in Proteobacteria abundance in the OVX rats (Bonferroni adjusted $p = 0.12$), at the family level, Bacteroidaceae, Erysipelotrichaceae, and Alcaligenaceae were lower in OVX ($q < 0.20$). The genera Bacteroides and Sutterella were also lower in the OVX rats ($q < 0.20$). Consistent with our analysis at the phylogenetic level, we did not observe any significant differences in fecal microbiome communities between OVX vehicle, LDN, or HDN groups at the taxonomic level. Finally, we were unable to identify any taxa that correlate with blood nitrate or nitrite levels, or bone status including cancellous BV/TV in proximal tibia metaphysis, cortical volume in tibia diaphysis, or total tibia BMD.

We also observed a non-significant increase in the abundance of Bacteroidetes in OVX animals (Bonferroni adjusted $p = 0.12$). At the family level, Bacteroidaceae, Erysipelotrichaceae, and Alcaligenaceae were lower in OVX ($q < 0.20$). The genera Bacteroides and Sutterella were also lower in the OVX rats ($q < 0.20$). Consistent with our analysis at the phylogenetic level, we did not observe any significant differences in fecal microbiome communities between OVX vehicle, LDN, or HDN groups at the taxonomic level. Finally, we were unable to identify any taxa that correlate with blood nitrate or nitrite levels, or bone status including cancellous BV/TV in proximal tibia metaphysis, cortical volume in tibia diaphysis, or total tibia BMD.
4 Discussion

The goal of this study was to evaluate the effects of dietary nitrate on bone in a rat model of OVX-induced bone loss. Three weeks of dietary nitrate supplementation in water at 0.1 mmol nitrate/kg bw/day or 1.0 mmol nitrate/kg bw/day to rats increased blood levels of nitrate in a dose-dependent fashion and to concentrations comparable to those in humans consuming high-nitrate fruit and vegetables (e.g., 0.1 mmol/kg/d equates to \( \sim 372 \) mg and 1.0 mmol/kg/d to 3.72 grams, respectively) [9]. Dietary nitrate concentrations of \( \sim 0.1 \) mmol/kg/d in rats have been demonstrated to lower blood pressure [16], and intakes of \( \sim 372 \) mg total nitrate per day reverse vascular dysfunction in older adult humans [42]. Three weeks of dietary nitrate supplementation, a period adequate to observe rapid OVX-associated bone loss and treatment-associated effects [43], had no effect on tibial cancellous or cortical bone mass and architecture or histomorphometric indices of bone formation or resorption in OVX rats. Furthermore, increased dietary nitrate had no significant effect on serum biochemical markers of bone turnover.

We are not aware of prior animal studies investigating dietary nitrate effects on bone mass and turnover. One in vitro study ascribed estrogenic activity to the nitrite anion in a transcription assay [44]. The relationship between NO and bone physiology is complex. Osteoclasts and osteoblasts both constitutively express the endothelial isoform of nitric oxide synthase (eNOS), implying a role for NO in bone metabolism. Exogenous nitrates like NTG may influence bone cells indirectly as NO donors. The molecular targets for NO in bone cells are poorly understood, although in vitro work suggests that NO has biphasic effects on both osteoclasts and osteoblasts, demonstrating the ability to stimulate or inhibit cell activity depending on the amount of NO present, as well as which NOS isoform is active [45–47]. Nitrates may also affect osteoclasts and osteoblasts; NO may influence osteoclast activity, in part, via the receptor activator of NF-kappaB ligand (RANKL)/osteoprotegerin (OPG) pathway. High levels of NO stimulate OPG, which binds to RANKL and prevents the binding of RANKL to the receptor activator of NF-kappaB (RANK), decreasing osteoclast activity [48]. eNOS global knockout animals exhibit lower BMD, bone formation, and osteoblast activity; with little to no effect on bone resorption, suggesting NO may be important for osteoblast function [49, 50]. Previous research shows NO synthesis is induced in osteoblasts and osteocytes by mechanical strain and shear stress [51–54].

Aging is associated with decreased eNOS-dependent NO synthesis and endothelium-dependent vasodilation [18]. Reduced cofactor availability for eNOS can decrease NO production [19]. Previous reports show that OVX significantly lowers plasma NO metabolite \([\text{NO}_x; \text{plasma nitrate+nitrite}]\) levels in rats [55]. In postmenopausal women receiving hormone replacement therapy (HRT), plasma NO\(_x\) levels are positively correlated with estrogen status [56]. Thus, age-associated decreases in NO production may contribute to osteoporosis risk. However, we did not observe a significant decrease in either blood nitrate or nitrite levels in OVX rats.

Studies in OVX rats show organic nitrates slow bone loss by reducing bone turnover [22–24]. Human data on organic nitrate effects on bone are generally concordant with the animal data, but there are conflicting results. A randomized controlled trial (RCT) to study the effects of NTG ointment compared to oral estrogen in oophorectomized women demonstrated that NTG was equivalent to a standard estrogen dose in preserving BMD [25]. Furthermore, NTG significantly decreased NTx (bone resorption) and increased serum osteocalcin and serum bone-specific alkaline phosphatase (bone formation) [25]. A follow-up RCT conducted in postmenopausal women reported equivalent effects of isosorbide mononitrate (20 mg/day) or alendronate...
suggesting that organic nitrate is able to increase BMD and slow bone turnover in humans. However, the Phase III clinical trial NOVEL, evaluating NTG on lumbar spine BMD in postmenopausal women, found no significant differences between the NTG and control groups after two years of intervention [27]. Poor compliance and suboptimal dose (22.5 mg NTG/day) potentially explain the null findings. Most patients were taking <15 mg of active NTG per day, far below the proposed therapeutic window for bone.

While both organic and inorganic nitrates mediate their principal effects through NO production, there are notable differences. Inorganic nitrates are small, water-soluble ions present in the diet and produced endogenously by oxidation of NO, while organic nitrates are synthetic and structurally more complex [57]. These structural differences, together with pharmacokinetic differences, may contribute to the observed differences in animal studies.

Dietary nitrates rely on lingual reduction of salivary nitrate via enterosalivary circulation [58], to produce nitrite and NO. Biotransformation of organic nitrates is not fully understood and can vary widely with the class of organic nitrate [59]. Organic nitrates typically undergo liver first-pass metabolism; however, the exact mechanism of denitration (release of NO) in the vasculature or different tissue sites remains a matter of debate [60, 61]. Organic nitrates have potent acute effects, while the metabolic conversion of inorganic nitrate to nitric oxide is more efficient under hypoxic and acidic conditions that may not have been reproduced under these study conditions [57]. Thus, differential metabolism may explain why dietary nitrate does not affect the estrogen-deficient skeleton in an analogous manner to organic nitrates. The form of supplemented nitrate may alter efficacy. For instance, vegetable juices were more efficacious than sodium nitrate in lowering blood pressure in humans, indicating that other components of vegetables may increase efficacy [62]. While we demonstrate that sodium nitrate has no effect on bone when supplemented in water, it remains unknown if nitrate-rich foods have a beneficial effect on the osteoporotic skeleton. Future studies should consider evaluation of nitrate-rich foods, supplementation prior to ovarian hormone deficiency, and inclusion of a positive control, such as organic nitrate, to show responsiveness to exogenous substrate for NO production in the animal model.

Salivary nitrate reduction to nitrite by nitrate reductases in lingual bacteria is one of the earliest examples of commensalism [13]. Prior work has demonstrated dietary nitrate can alter oral microbiome composition [63, 64]. However, little is known about interaction between dietary nitrate and the gut microbiome. Certain probiotic bacterial strains have been shown to generate NO within the gastrointestinal tract, highlighting the physiological context-dependence of the nitrate-nitrite-nitric oxide cycle [29]. Given the ability of diet to modulate the gut microbiome, and the gut microbiome’s association with bone mass, we evaluated the ability of dietary nitrate to influence fecal microbiome composition. We did not observe significant differences in fecal microbiome composition or diversity between OVX vehicle, LDN, or HDN groups (Fig. 3A). However, variation in cellular abundance of the microbiome could exist. It is also possible that OVX effects overwhelm the effects of the dietary nitrate-related gut microbiome, or that nitrate is influencing the gut microbiome in a region of the gut that is not well represented by the stool microbiome, as nitrate is largely absorbed in the upper small intestine [11].

We did observe differences in fecal microbiome composition between OVX and sham controls. An accumulating body of literature suggests a role for the gut microbiome in the regulation of bone mass. For instance, germ-free (GF) mice have significantly increased bone mass compared to conventionally raised mice [65]. Further, OVX GF mice are protected from cancellous and cortical bone loss [30]. Since altered microbiome composition is associated with chronic disease and that specific microbiota interacts with the immune system [66–70], it has been hypothesized that gut microbiome composition may influence the magnitude of bone loss in postmenopausal women [30]. Sex steroid deficiency results in a chronic inflammatory state that may contribute to osteoporosis [71]. The microbiome’s effects on bone mass may be mediated via alteration of the immune system and regulation of osteoclastogenesis, which results in greater bone loss in postmenopause when women lose the immunosuppressive effects of estrogen [30, 72, 73]. This evidence suggests a putative role of the gut microbiome in the bone loss observed in sex-steroid deficiency. Currently, our understanding of OVX-related changes in the composition of the enteric microbiome in rats is limited to one study. Characterizing this relationship is useful given the growing body of literature that posits a relationship between bone mass and the gut microbiome [28, 30, 31]. York et al. characterized fecal microbial composition of low- and high-aerobic capacity rats in relation to OVX [74]. They found phylum level differences and a significantly lower Firmicutes:Bacteroidetes (F:B) ratio in OVX rats.

We observed differences in the community structure of the fecal microbiome between sham and OVX rats (Fig. 3B). We also identified specific taxa that stratify OVX and sham animals, and observed increased Firmicutes abundance in OVX compared to sham (p = 0.015). In contrast to York et al., we observed a significantly higher F:B ratio associated with OVX (p = 0.03). This result indicates that the F:B statistic may not robustly associate with OVX status and may be subject to study effects, as has been observed in microbiome investigations of obesity [75, 76]. Future work should consider how specific organisms within the Bacteroidetes and Firmicutes phyla interact with estrogen-related processes in the gut. York et al. did not report evaluation of phylotype differences in their analyses. We found the Bacteroidaceae and Alcaligenaceae families were significantly lower in abundance in OVX compared to sham. Both of these families are associated with estrogen metabolism. Estrogens have been demonstrated to foster growth of Bacteroidaceae in the oral cavity [77] and
Alcaligenaceae has been shown to metabolize estradiol in vitro [78]. Our observations are consistent with this work, as reductions of these families are associated with reduced estrogen levels. Estrogen metabolites are directly exposed to the gut microbiome through enterohepatic circulation, but very little is known about the direct interactions between estrogens and the gut microbiome. Future investigations are required to determine whether there is a causal role of the gut microbiome in bone loss in O VX [30, 74, 79] and to explore specific mechanisms by which the gut microbiome may effect bone metabolism in sex-steroid deficiency.

We thank Drs. Carmen Wong and Ajay Maccha, and Ms. Dawn Olson for their technical assistance during experiments and data analyses and to the members of both the Sharpton and Skeletal Biology Laboratories for helpful discussion of the manuscript. We are also thankful to the Oregon State University Center for Genome Research and Biocomputing for their sequencing support and Stephen Lawson for helpful discussion and proofreading of the manuscript.

M.C., N.H., U.I., and T.S. conceived and designed the experiments. M.C., C.R., and A.M. carried out the animal studies. M.C. analyzed the data. M.C. wrote the manuscript. M.C., U.I., T.S., and N.H. edited the manuscript.

This work was supported by the NSF (DGE-0956280), the Celia Strickland Austin and G. Kenneth Austin III Endowed Professorship in Public Health and Human Sciences, and the OSU Environmental Health Sciences Core Center Pilot Project Program. Ms. Sara Kerr created the graphic representation of the results for this manuscript.

Note: The acknowledgement was updated on May 4, 2017.

The authors have declared no conflicts of interest.

5 References

[1] Randell, A. G., Nguyen, T. V., Bhalerao, N., Silverman, S. L. et al., Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int. J. Establ. Result Coop. Eur. Found. Osteoporos Natl. Osteoporos Found USA 2000, 11, 460–466.

[2] Harris, S. T., Jaffe, R. B., Shoback, D., Menopause and bone loss. J. Clin. Endocrinol. Metab. 2006, 91, E1–E2.

[3] Cummings, S. R., Browner, W., Cummings, S. R., Black, D. M. et al., Bone density at various sites for prediction of hip fractures. Lancet 1993, 341, 72–75.

[4] Tucker, K. L., Hannan, M. T., Chen, H., Cupples, L. A. et al., Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am. J. Clin. Nutr. 1999, 69, 727–36.

[5] New, S. A., Robins, S. P., Campbell, M. K., Martin, J. C. et al., Dietary influences on bone mass and bone metabolism: further evidence of a positive link between fruit and vegetable consumption and bone health? Am. J. Clin. Nutr. 2000, 71, 142–151.

[6] Pryne, C. J., Mishra, G. D., O’Connell, M. A., Muniz, G. et al., Fruit and vegetable intakes and bone mineral status: a cross sectional study in 5 age and sex cohorts. Am. J. Clin. Nutr. 2006, 83, 1420–1428.

[7] New, S. A., Bolton-Smith, C., Grubb, D. A., Reid, D. M., Nutritional influences on bone mineral density: a cross-sectional study in premenopausal women. Am. J. Clin. Nutr. 1997, 65, 1831–1839.

[8] Macdonald, H. M., New, S. A., Golden, M. H. N., Campbell, M. K. et al., Nutritional associations with bone loss during the menopausal transition: evidence of a beneficial effect of calcium, alcohol, and fruit and vegetable nutrients and of a detrimental effect of fatty acids. Am. J. Clin. Nutr. 2004, 79, 155–165.

[9] Hord, N. G., Tang, Y., Bryan, N. S., Food sources of nitrates and nitrites: the physiologic context for potential health benefits. Am. J. Clin. Nutr. 2009, 90, 27131.

[10] European Food Safety Authority. Nitrate in vegetables: scientific opinion of the panel on contaminants in the food chain. EFSA J. 2008, 6, 1–79.

[11] Lundberg, J. O., Weitzberg, E., Gladwin, M. T., The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nat. Rev. Drug Discov. 2008, 7, 156–167.

[12] Lundberg, J. O., Weitzberg, E., Cole, J. A., Benjamin, N., Nitrate, bacteria and human health. Nat. Rev. Microbiol. 2004, 2, 593–602.

[13] Hord, N. G., Regulation of dietary nitrate and nitrite: balancing essential physiological roles with potential health risks. In: N. S. Bryan, J. Loscalzo, (Eds), Nitrite Nitrate Human Health Disease, Humana Press, New York, 2011, pp. 155–166.

[14] Hernández-Ramírez, R. U., Galván-Portillo, M. V., Ward, M. H., Agudo, A. et al., Dietary intake of polyphenols, nitrate and nitrite and gastric cancer risk in Mexico City. Int. J. Cancer 2009, 125, 1424–1430.

[15] Moncada, S., Higgs, A., The L-arginine-nitric oxide pathway. N. Engl. J. Med. 1993, 329, 2002–2012.

[16] Carlström, M., Liu, M., Yang, T., Zollbrecht, C. et al., Cross-talk between nitrate-nitrite-NO and NO synthase pathways in control of vascular NO homeostasis. Antioxid. Redox Signal. 2015, 23, 295–306.

[17] Ahluwalia, A., Gladwin, M., Coleman, G. D., Hord, N. et al., Dietary nitrate and the epidemiology of cardiovascular disease: report from a national heart, lung, and blood institute workshop. J. Am. Heart Assoc. 2016, 5, e003402.

[18] Delp, M. D., Behnke, B. J., Spier, S. A., Wu, G. et al., Ageing diminishes endothelium-dependent vasodilatation and tetrahydrobiopterin content in rat skeletal muscle arterioles. J. Physiol. 2008, 586, 1161–1168.

[19] Yang, Y.-M., Huang, A., Kaley, G., Sun, D., eNOS uncoupling and endothelial dysfunction in aged vessels. Am. J. Physiol. Heart Circ. Physiol. 2009, 297, H1829–H1836.

[20] Jamali, S. A., Browner, W. S., Bauer, D. C., Cummings, S. R., Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J. Bone Miner. Res. 1998, 13, 1755–1769.
[21] Bode-Böger, S. M., Kojda, G., Organic nitrates in cardiovascular disease. Cell Mol. Biol. Noisy–Gd. Fr. 2005, 51, 307–320.

[22] Wimalawansa, S. J., De Marco, G., Gangula, P., Yallampalli, C., Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 1996, 18, 301–304.

[23] Wimalawansa, S., Chapa, T., Fang, L., Yallampalli, C. et al., Frequency-dependent effect of nitric oxide donor nitroglycerin on bone. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2000, 15, 1119–1125.

[24] Wimalawansa, S. J., Restoration of ovariectomy-induced osteopenia by nitroglycerin. Calcif. Tissue Int. 2000, 66, 56–60.

[25] Wimalawansa, S. J., Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2000, 15, 2240–2244.

[26] Nabhan, A. F., Rabie, N. H., Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. Int. J. Gynecol. Obstet. 2008, 103, 213–216.

[27] Wimalawansa, S. J., Grimes, J. P., Wilson, A. C., Hoover, D. R., Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J. Clin. Endocrinol. Metab. 2009, 94, 3356–3364.

[28] Weaver, C. M., Diet, gut microbiome, and bone health. Curr. Osteoporos Rep. 2015, 13, 125–130.

[29] Sobko, T., Huang, L., Midtvedt, T., Norin, E. et al., Generation of NO by probiotic bacteria in the gastrointestinal tract. Free Radic. Biol. Med. 2006, 41, 985–991.

[30] Ohlsson, C., Sjögren, K., Effects of the gut microbiota on bone mass. Trends Endocrinol. Metab. 2015, 26, 69–74.

[31] Charles, J. F., Ermann, J., Aliprantis, A. O., The intestinal microbiome and skeletal fitness: connecting bugs and bones. Clin. Immunol. Orlando Fla. 2015, 159, 163–169.

[32] Piknova, B., Schechter, A. N., Measurement of nitrite in blood samples using the ferricyanide-based hemoglobin oxidation assay. Methods Mol. Biol. Clifton NJ 2011, 704, 39–56.

[33] Wimalawansa, S. J., De Marco, G., Gangula, P., Yallampalli, C., Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 1996, 18, 301–304.

[34] Wimalawansa, S. J., Restoration of ovariectomy-induced osteopenia by nitroglycerin. Calcif. Tissue Int. 2000, 66, 56–60.

[35] Wimalawansa, S. J., Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2000, 15, 2240–2244.

[36] Weaver, C. M., Diet, gut microbiome, and bone health. Curr. Osteoporos Rep. 2015, 13, 125–130.

[37] Ohlsson, C., Sjögren, K., Effects of the gut microbiota on bone mass. Trends Endocrinol. Metab. 2015, 26, 69–74.

[38] Charles, J. F., Ermann, J., Aliprantis, A. O., The intestinal microbiome and skeletal fitness: connecting bugs and bones. Clin. Immunol. Orlando Fla. 2015, 159, 163–169.

[39] Piknova, B., Schechter, A. N., Measurement of nitrite in blood samples using the ferricyanide-based hemoglobin oxidation assay. Methods Mol. Biol. Clifton NJ 2011, 704, 39–56.

[40] Wos-Oxley, M., Oxley, A. P. A., Kahl, S. et al., Comparative evaluation of establishing a human gut microbial community within rodent models. Gut Microbes 2012, 3, 234–249.

[41] Nguyen, T. L. A., Vieira-Silva, S., Liston, A., Raes, J., How informative is the mouse for human gut microbiota research? Dis. Model. Mech. 2015, 8, 1–16.

[42] Rammes, C., Hendgen-Cotta, U. B., Sobierajski, J., Bernard, A. et al., Dietary nitrate reverses vascular dysfunction in older adults with moderately increased cardiovascular risk. J. Am. Coll. Cardiol. 2014, 63, 1584–1585.

[43] Sibonga, J. D., Evans, G. L., Hauck, E. R., Bell, N. H. et al., Ovarian status influences the skeletal effects of tamoxifen in adult rats. Breast Cancer Res. Treat. 1996, 41, 71–79.

[44] Veselik, D. J., Divekar, S., Dakshanamurthy, S., Storchan, G. B. et al., Activation of estrogen receptor-alpha by the anion nitrite. Cancer Res 2008, 68, 3950–3958.

[45] Riancho, J. A., Salas, E., Zarrabeitia, M. T., Olmos, J. M. et al., Expression and functional role of nitric oxide synthase in osteoblast-like cells. J Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 1995, 10, 439–446.

[46] Ralston, S. H., Todd, D., Helfrich, M., Benjamin, N. et al., Human osteoblast-like cells produce nitric oxide and express inducible nitric oxide synthase. Endocrinology 1994, 135, 330–336.

[47] Ralston, S. H., Ho, L. P., Helfrich, M. H., Grabowski, P. S. et al., Nitric oxide: a cytokine-induced regulator of bone resorption. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 1995, 10, 1040–1049.

[48] Zheng, H., Yu, X., Collin-Osdoby, P., Osdoby, P., RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis and bone resorption. J. Biol. Chem. 2006, 281, 15809–15820.

[49] Armour, K. E., Armour, K. J., Gallagher, M. E., Gödecke, A. et al., Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 2001, 142, 760–766.

[50] Bode-Böger, S. M., Kojda, G., Organic nitrates in cardiovascular disease. Cell Mol. Biol. Noisy–Gd. Fr. 2005, 51, 307–320.

[51] Wos-Oxley, M., Oxley, A. P. A., Kahl, S. et al., Comparative evaluation of establishing a human gut microbial community within rodent models. Gut Microbes 2012, 3, 234–249.

[52] Klein-Nulend, J., van der Plas, A., Semeins, C. M., Ajubi, N. et al., Organic nitrates in cardiovascular disease. Cell Mol. Biol. Noisy–Gd. Fr. 2005, 51, 307–320.

[53] Klein-Nulend, J. van der Plas, A., Semeins, C. M., Ajubi, N. et al., Organic nitrates in cardiovascular disease. Cell Mol. Biol. Noisy–Gd. Fr. 2005, 51, 307–320.

[54] Klein-Nulend, J., van der Plas, A., Semeins, C. M., Ajubi, N. et al., Organic nitrates in cardiovascular disease. Cell Mol. Biol. Noisy–Gd. Fr. 2005, 51, 307–320.
oxide in osteoblasts. Am. J. Physiol. 1996, 271, E205–E208.

[54] Zaman, G., Pitsillides, A. A., Rawlinson, S. C., Suswillo, R. F. et al., Mechanical strain stimulates nitric oxide production by rapid activation of endothelial nitric oxide synthase in osteocytes. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 1999, 14, 1123–1131.

[55] van Bezoijen, R. L., Que, I., Ederveen, A. G., Kloosterboer, H. J. et al., Plasma nitrate+nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats. J. Endocrinol. 1998, 159, 27–34.

[56] Bednarek-Tupikowska, G., Twarowska-Bardzinska, U., Tupikowski, K., Effects of estrogen and estrogen-progesteron on serum nitric oxide metabolite concentrations in post-menopausal women. J. Endocrinol. Invest. 2008, 31, 877–881.

[57] Omar, S. A., Artime, E., Webb, A. J., A comparison of organic and inorganic nitrates/nitrates. Nitric Oxide 2012, 26, 229–240.

[58] Spiegelhalder, B., Eisenbrand, G., Preussmann, R., Influence of dietary nitrate on nitrite content of human saliva: possible relevance to in vivo formation of N-nitroso compounds. Food Cosmet. Toxicol. 1976, 14, 545–548.

[59] Münzelt, T., Daiber, A., Gori, T., Nitrate therapy new aspects concerning molecular action and tolerance. Circulation 2011, 123, 2123–2144.

[60] Govoni, M., Tocchetti, P., Lundberg, J. O., Metabolism and pathways for denitrification of organic nitrates in the human liver. J. Pharmacol. Exp. Ther. 2013, 346, 96–104.

[61] Page, N. A., Fung, H.-L., Organic nitrate metabolism and action: toward a unifying hypothesis and the future—a dedication to Professor Leslie Z. Benet. J. Pharm. Sci. 2013, 102, 3070–3081.

[62] Jonvik, K. L., Nyakayiru, J., Pinckaers, P. J., Senden, J. M. et al., Nitrate-rich vegetables increase plasma nitrate and nitrite concentrations and lower blood pressure in healthy adults. J. Nutr. 2016, 146, jn229807.

[63] Hyde, E. R., Luk, B., Cron, S., Kusic, L. et al., Characterization of the rat oral microbiome and the effects of dietary nitrate. Free Radic. Biol. Med. 2014, 77, 249–257.

[64] Koopman, J. E., Buiks, M. J., Brandt, B. W., Keijser, B. J. F. et al., Nitrate and the origin of saliva influence composition and short chain fatty acid production of oral microcosms. Microb. Ecol. 2016, 72, 479–492.

[65] Sjögren, K., Engdahl, C., Henning, P., Lerner, U. H. et al., The gut microbiota regulates bone mass in mice. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2012, 27, 1357–1367.

[66] Ley, R. E., Turnbaugh, P. J., Klein, S., Gordon, J. I., Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444, 1022–1023.

[67] Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V. et al., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444, 1027–1131.

[68] Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A. et al., Intestinal microbati metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013, 19, 576–585.

[69] Gregory, J. C., Buffa, J. A., Org, E., Wang, Z. et al., Transmission of atherosclerosis susceptibility with gut microbiota transplantation. J. Biol. Chem. 2015, 290, 5647–5660.

[70] Hooper, L. V., Littman, D. R., Macpherson, A. J., Interactions between the microbiota and the immune system. Science 2012, 336, 1268–1273.

[71] Manolagas, S. C., From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr. Rev. 2010, 31, 286–300.

[72] Charatcharoenwitthaya, N., Khosla, S., Atkinson, E. J., McCready, L. K. et al., Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early post-menopausal women. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2007, 22, 724–729.

[73] Li, J.-Y., Tawfeek, H., Bedi, B., Yang, X. et al., Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc. Natl. Acad. Sci. U S A 2011, 108, 768–773.

[74] Cox-York, K. A., Shefiin, A. M., Foster, M. T., Gentile, C. L. et al., Ovariectomy results in differential shifts in gut microbiota in low versus high aerobic capacity rats. Physiol. Rep. 2015, 3. https://doi.org/10.14814/phy2.12488.

[75] Finucane, M. M., Sharpton, T. J., Laurent, T. J., Pollard, K. S., A taxonomic signature of obesity in the microbiome? Getting to the guts of the matter. PloS One 2014, 9, e84689.

[76] Sze, M. A., Schloss, P. D., Looking for a signal in the noise: revisiting obesity and the microbiome. mBio 2016, 7, e01018–e01016.

[77] Kornman, K. S., Loeche, W. J., Effects of estradiol and progesterone on Bacteroides melaninogenicus and Bacteroides gingivalis. Infect. Immun. 1982, 13, 256–263.

[78] Payne, D. W., Talalay, P., Isolation of novel microbial 3 alpha-, 3 beta-, and 17 beta-hydroxysteroid dehydrogenases. Purification, characterization, and analytical applications of a 17 beta-hydroxysteroid dehydrogenase from an Alcaligenes sp. J. Biol. Chem. 1985, 260, 13648–13655.

[79] Nobel, Y. R., Cox, L. M., Kirigin, F. F., Bokulich, N. A. et al., Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment. Nat. Commun. 2015, 6, 7486.